Bayer's Rally Reaches a Crossroads: Pipeline Hopes and Trade Storm Clouds Collide
02.07.2026 - 09:12:10 | boerse-global.de
Bayer shares have nearly doubled from last year’s lows, but the advance is now testing the nerves of even the most bullish investors. The stock closed at €48.77 on Wednesday, less than 3% shy of its 52-week peak of €49.93, after a 28% year-to-date surge. The catalyst is clear: a string of legal victories in the glyphosate saga has lifted a heavy tail risk. Yet with the Relative Strength Index hitting 80.5 and a new U.S. trade investigation targeting German drug prices, the rally is entering a precarious phase.
The Bull Case: Relief and Pipeline Promise
The Supreme Court’s decision to block certain glyphosate claims has been hailed as a “big win” by Bank of America, which reiterated its Buy rating on June 26. DZ Bank and UBS have kept the stock in their top picks among European pharma names. The market is now pricing in a worst-case scenario for the Roundup litigation, allowing investors to refocus on Bayer’s operational story.
That story hinges on the pharma pipeline. The anticoagulant Xarelto, once a cash cow, saw revenue plunge by a third to $2.6 billion in 2025 after key patents expired. The successor, Asundexian, is designed to prevent strokes and has already won accelerated review from the FDA, which accepted the application in May. The European Medicines Agency is also evaluating the drug. A smooth approval process could recast Bayer as a growth story rather than a litigation liability.
Further bolstering the pipeline narrative, the FDA recently approved Bayer’s contrast agent Gadoquatran. A string of positive R&D news could lure back institutional buyers who fled during the legal turmoil.
Should investors sell immediately? Or is it worth buying Bayer?
Countercurrents: Overbought Signals and a Divided Analyst Camp
But the technical picture screams caution. The 14-day RSI of 80.5 marks one of the most overbought readings in recent memory, and the annualized volatility of nearly 60% makes the stock vulnerable to sharp pullbacks. The shares trade 32% above their 200-day moving average and 27% above the 50-day line — levels that historically precede at least a short-term correction.
Analysts are split. On the same day UBS reaffirmed its Buy, AlphaValue/Baader Europe downgraded Bayer to Reduce, arguing that the current price already reflects the legal relief and leaves little upside from here. The downgrade stands out against a backdrop of mostly bullish ratings, but it highlights a growing concern: how much of the good news is already baked in?
A New Front Opens in U.S.-EU Trade Tensions
Adding to the uncertainty, the U.S. Trade Representative has launched an investigation into German drug pricing, with a public hearing scheduled for September 22, 2026. If the probe leads to punitive measures, retaliatory tariffs on German pharmaceutical imports could take effect as early as July 31, 2026 — just days before Bayer’s second-quarter earnings report in August. The tariffs would compound existing Section 232 levies imposed in April, part of a broader escalation in U.S. trade policy toward the European Union.
For Bayer, already burdened by net debt and ongoing litigation cash outflows, such a development would hit at a moment when the stock is priced for perfection. The Supreme Court victory removed the single biggest tail risk, but it did not eliminate the legal overhang entirely: lower courts are still weighing other claims, and the EPA’s classification of glyphosate as non-carcinogenic — Bayer’s primary defense — could shift under political pressure.
Bayer at a turning point? This analysis reveals what investors need to know now.
What Comes Next: July 9 and Beyond
The immediate test comes on July 9, when a court hears arguments on final approval of a multibillion-dollar class settlement in the glyphosate complex. That decision will heavily influence the stock’s near-term trajectory. Should it pass without a hitch, the rally could extend further, especially if Asundexian’s regulatory process continues smoothly.
Should it stumble — or should the USTR probe start generating negative headlines — the overbought technicals and high volatility would likely trigger a sharp correction. For now, the majority of analysts side with the bulls, but one dissenting voice has already warned that the easy money has been made. The next few weeks will show whether Bayer’s pipeline can carry the weight that its legal victories have placed on its shoulders.
Ad
Bayer Stock: New Analysis - 2 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
